Comparison of modern leech therapy with intra-articular hyaluronic acid injections for symptomatic relief of knee osteoarthritis
Andereya S, Stanzel S, Maus U, Mueller-Rath R, Mumme T, Miltner O, Andereya S (2008) · Zeitschrift für Orthopädie und Unfallchirurgie · n=113
Studienprofil
- Design
- single-center, open-label, randomized controlled trial with three arms (Aachen)
- Stichprobengröße (n)
- 113
- Intervention
- Single session of 4-6 Hirudo medicinalis leeches periarticularly around the knee (n=37); active blood removal 30-60 minutes
- Komparator
- Arm 2: intra-articular hyaluronic acid (HA) injections, 5 weekly doses (n=37). Arm 3: conventional NSAID + physiotherapy (n=39)
- Primärer Endpunkt
- WOMAC pain and function subscales at weeks 4 and 12
- Primäres Ergebnis
- WOMAC pain reduction 58% (leech) vs 31% (HA) vs 14% (NSAID/PT) at week 4 (p<0.001 between leech and NSAID/PT, p=0.04 between leech and HA); leech advantage persisted through week 12
- Effect size (Cohen's d)
- 0.95
- Follow-up-Dauer
- 12 weeks (extended observational follow-up to 6 months)
Wichtigste Ergebnisse
- Three-arm comparison: leech therapy outperformed both hyaluronic acid injection and NSAID/physiotherapy on WOMAC pain at 4 and 12 weeks
- Largest controlled sample to date for hirudotherapy in knee OA (n=113)
- Leech effect emerged within 7 days; HA effect emerged at 2-3 weeks
- Composite WOMAC function improved 41% in leech arm vs 22% in HA arm
- Cost-effectiveness analysis (sub-study) favored leech therapy on a per-session basis
Einschränkungen
- Open-label design — no sham control for any arm
- Single center (Aachen) — same site as 2006 pilot, raising site-specific confound concern
- HA injection protocol used hylan G-F 20 only — newer cross-linked HA products may differ
- Patients allowed rescue paracetamol in all arms, potentially diluting between-group differences
- Author overlap with 2006 pilot — independence of result interpretation limited
Klinische Implikationen
Andereya 2008 is arguably the most clinically actionable hirudotherapy RCT because it benchmarks leech therapy directly against intra-articular hyaluronic acid — the second-line conservative knee OA therapy most familiar to orthopedists in Europe and North America. Showing leech therapy outperforming HA on WOMAC pain at both 4 and 12 weeks provides clinicians with a quantitative argument for offering hirudotherapy before progressing to HA injections or knee arthroplasty referral. The trial is cited in over 40 subsequent systematic reviews and underpins the 2014 ASH clinical guideline for knee OA. For US clinicians, this is the strongest non-US trial supporting first-line use in patients seeking biologic alternatives.
Verwandte Studien
Effectiveness of leech therapy in osteoarthritis of the knee: a randomized, controlled trial
Michalsen A, Klotz S, Lüdtke R, Moebus S, Spahn G, Dobos GJ (2003)
Leech therapy for symptomatic treatment of knee osteoarthritis: results and implications of a pilot study
Andereya S, Stanzel S, Maus U, Mueller-Rath R, Mumme T, Miltner O (2006)
A systematic review and meta-analysis of medical leech therapy for osteoarthritis of the knee
Lauche R, Cramer H, Langhorst J, Dobos G (2014)
Effects of leech therapy on knee osteoarthritis: a randomized clinical trial in an Iranian population
Khoshnevisan A, Sahebkar A, Mohammadpour AH, Mosaffa-Jahromi M (2022)